Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-GLOD4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GLOD4 also known as Glyoxalase Domain Containing 4 is a protein with a significant role in cellular processes. It has a molecular mass of approximately 18 kDa. This protein expresses mainly in the liver brain and kidneys indicating its involvement in multiple organ systems. GLOD4 contains characteristic glyoxalase domains which facilitate its biochemical actions. Studies suggest that GLOD4 structurally participates in stress response and detoxification pathways due to these domain properties.
Biological function summary
Glyoxalase Domain Containing 4 plays important roles in the detoxification of methylglyoxal a byproduct of glycolysis that can be harmful at high levels. GLOD4 does not function alone; it acts as part of the glyoxalase system which includes other Gly and Gly-related enzymes to efficiently convert toxic metabolites into non-toxic substances. Its enzymatic actions support the maintenance of cellular homeostasis and protection against glycation end-products that are damaging to cellular structures.
Pathways
Glyoxalase Domain Containing 4 operates within key metabolic routes like the glycolytic pathway and the detoxification pathway. It collaborates with enzymes like Glyoxalase I and Glyoxalase II in the aforementioned glyoxalase system to perform its roles. The action within these pathways helps reduce oxidative stress aiding in the prevention of cellular damage. GLOD4’s interaction with these enzymes and pathways highlights its importance in maintaining cellular integrity under physiological and stress conditions.
Elevated Glyoxalase Domain Containing 4 expression links to conditions such as diabetes and neurodegenerative disorders. Changes in GLOD4 levels often correspond with disruptions in methylglyoxal metabolism and oxidative stress common in these diseases. Studies also indicate relationships among GLOD4 insulin signaling and proteins such as Glyoxalase I suggesting a connection to the metabolic disturbances found in diabetes. GLOD4's involvement in detoxification pathways also affects the pathogenesis of neurodegenerative diseases potentially influencing cell survival and neuroprotection mechanisms.
